pasireotide sold brand name signifor orphan drug approved united european treatment cushings disease patients fail ineligible surgical developed novartis pasireotide somatostatin analog increased affinity somatostatin receptor compared somatostatin analogs common side effects include hyperglycaemia high blood sugar levels diabetes diarrhoea abdominal pain stomach ache nausea feeling sick cholelithiasis gallstones injection site reactions pasireotide approved cushings disease european medicines agency ema april us food drug administration fda december pasireotide lar longactingrelease formulation approved fda treatment acromegaly december approved indication ema september hormonal preparation article stub help wikipedia expanding httpsenwikipediaorgwikipasireotide